We did not observe a significant difference in breast cancer-specific deaths between the BCSNR and MALND groups; furthermore, there were no significant differences in breast cancer-specific deaths among patients with luminal type, HER2-enriched, and TNBC between the groups. This evidence concerns the gene ERBB2 and breast cancer.